Bridger Management LLC Has Raised Its Medicines Co (MDCO) Holding

March 15, 2018 - By Peter Erickson

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.44, from 1.22 in 2017Q2. It dropped, as 32 investors sold MDCO shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. 272,210 are held by Ashford Capital Management. 26,068 are held by Whittier Tru. Brown Advisory Inc holds 0% or 6,974 shares. Wells Fargo And Mn stated it has 0% in The Medicines Company (NASDAQ:MDCO). Nationwide Fund Advisors holds 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 68,238 shares. Texas Permanent School Fund, a Texas-based fund reported 46,666 shares. Rhumbline Advisers has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Eagle Asset Mngmt owns 814,434 shares. Twin Focus Prns Lc stated it has 26,000 shares. Iridian Asset Management Limited Liability Company Ct has 1.76M shares. Citigroup stated it has 2,967 shares or 0% of all its holdings. Ny State Common Retirement Fund has 161,297 shares. Moreover, State Teachers Retirement has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 147,007 shares. Ameritas Inv Ptnrs has 0.01% invested in The Medicines Company (NASDAQ:MDCO). Mutual Of America Capital Ltd has 58,651 shares for 0.04% of their portfolio.

Since December 7, 2017, it had 1 buying transaction, and 1 insider sale for $1.60 million activity. MEANWELL CLIVE sold 136,250 shares worth $3.71M.

Roberto Mignone increased its stake in Medicines Co (MDCO) by 14.13% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc bought 347,714 shares as the company’s stock declined 20.30% while stock markets rallied. The hedge fund run by Roberto Mignone held 2.81M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $104.04M, up from 2.46 million at the end of the previous reported quarter. Bridger Management Llc who had been investing in Medicines Co for a number of months, seems to be bullish on the $2.52 billion market cap company. The stock decreased 0.98% or $0.34 during the last trading session, reaching $34.43. About 708,495 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since March 15, 2017 and is uptrending. It has by 0.00% the S&P500.

Bridger Management Llc, which manages about $3.11B and $1.67 billion US Long portfolio, decreased its stake in Charter Communications Inc N by 21,978 shares to 116,109 shares, valued at $42.20M in 2017Q3, according to the filing. It also reduced its holding in Facebook Inc (NASDAQ:FB) by 95,177 shares in the quarter, leaving it with 226,328 shares, and cut its stake in Envision Healthcare Corp.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: which released: “The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and …” on February 21, 2018, also with their article: “The Medicines Company: The Upcoming ODYSSEY Trial Results Could Make It A More …” published on March 08, 2018, published: “The Medicines Company to Participate in the Cowen 38” on March 08, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: and their article: “The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule” published on February 20, 2018 as well as‘s news article titled: “Activist Alex Denner to gain board control at Medicines Co.” with publication date: March 01, 2018.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. The Medicines Co has $85.0 highest and $40.0 lowest target. $53.55’s average target is 55.53% above currents $34.43 stock price. The Medicines Co had 36 analyst reports since August 28, 2015 according to SRatingsIntel. The company was maintained on Tuesday, September 12 by Jefferies. The rating was maintained by JP Morgan with “Buy” on Saturday, August 29. The firm has “Buy” rating by Guggenheim given on Monday, October 23. As per Wednesday, November 4, the company rating was initiated by Chardan Capital Markets. The stock of The Medicines Company (NASDAQ:MDCO) earned “Outperform” rating by RBC Capital Markets on Monday, August 31. The stock has “Buy” rating by Chardan Capital Markets on Wednesday, August 30. The firm has “Neutral” rating by Citigroup given on Monday, July 17. Citigroup maintained The Medicines Company (NASDAQ:MDCO) rating on Wednesday, July 26. Citigroup has “Neutral” rating and $45 target. The stock of The Medicines Company (NASDAQ:MDCO) has “Buy” rating given on Tuesday, October 10 by Cowen & Co. The company was maintained on Tuesday, July 25 by H.C. Wainwright.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.